Table 1.
Baseline characteristics
| Characteristics | Placebo (n = 8566) | Rosuvastatin (n = 8554) | Atrial fibrillation (n = 238) | No Atrial fibrillation (n = 16 882) | P-value |
|---|---|---|---|---|---|
| Age, years | 66.0 (60–71) | 66.0 (60–71) | 70.0 (64–76) | 66.0 (60–71) | <0.0001 |
| Female | 3237 (37.8) | 3274 (38.3) | 71 (29.8) | 6440 (38.2) | 0.01 |
| Race | |||||
| White | 6034 (70.4) | 6055 (70.8) | 215 (90.3) | 11 874 (70.3) | <0.0001 |
| Black | 1111 (13.0) | 1086 (12.7) | 6 (2.5) | 2191 (13.0) | |
| Asian | 136 (1.6) | 146 (1.7) | 1 (0.4) | 281 (1.7) | |
| Hispanic | 1114 (13.0) | 1093 (12.8) | 13 (5.5) | 2194 (13.0) | |
| Other | 171 (2.0) | 172 (2.0) | 3 (1.3) | 340 (2.0) | |
| Current smoking | 1384 (16.2) | 1369 (16.0) | 33 (13.9) | 2720 (16.1) | 0.35 |
| Hypertension | 4921 (57.5) | 4864 (56.9) | 159 (66.8) | 9626 (57.1) | 0.003 |
| Systolic blood pressure, mmHg | 134 (124–145) | 134 (124–145) | 134 (126–145) | 134 (124–145) | 0.61 |
| Diastolic blood pressure, mmHg | 80 (75–87) | 80 (75–87) | 80 (72–85) | 80 (75–87) | 0.002 |
| Body mass index, kg/m2 | 28.3 (25.2–32.0) | 28.3 (25.3–32.0) | 29.6 (25.5–33.5) | 28.4 (25.3–32.0) | 0.02 |
| Baseline lipids, mg/dL | |||||
| Total cholesterol | 185 (169–199) | 186 (168–200) | 181 (162–198) | 185 (169–200) | 0.01 |
| LDL-C | 108 (94–119) | 108 (94–119) | 106 (91–117) | 108 (94–119) | 0.08 |
| HDL-C | 49 (40–60) | 49 (40–59) | 48 (40–58) | 49 (40–60) | 0.17 |
| Triglycerides | 118 (86–170) | 118 (85–169) | 111 (83–166) | 118 (86–170) | 0.22 |
| High-sensitivity C-reactive protein, mg/L | 4.3 (2.9–7.2) | 4.2 (2.8–7.1) | 5.0 (3.3–7.8) | 4.3 (2.8–7.1) | 0.0009 |
| Metabolic syndrome | 3584 (42.1) | 3519 (41.5) | 112 (47.9) | 6991 (41.2) | 0.06 |
| Alcohol intake | |||||
| <1–3 month | 4953 (57.8) | 5026 (58.8) | 146 (61.3) | 9833 (58.3) | 0.41 |
| 1–6 week | 1969 (23.0) | 1950 (22.8) | 46 (19.3) | 3873 (23.0) | |
| Daily | 1641 (19.2) | 1574 (18.4) | 46 (19.3) | 3169 (18.8) | |
| Exercise | |||||
| <1/week | 4876 (57.0) | 4750 (56.0) | 150 (63.0) | 9476 (56.2) | 0.04 |
| ≥1/week | 3687 (43.0) | 3799 (44.4) | 88 (37.0) | 7398 (43.8) | |
Values are median (inter-quartile range) or n (%). P-values refer to comparisons between participants who developed AF and those who did not develop AF during study follow-up. Race is self-reported. Hypertension was defined as blood pressure ≥140/90 mmHg or taking anti-hypertensive agents. The metabolic syndrome was defined according to consensus criteria of the National Heart, Lung, Blood Institute and American Heart Association. Values of high-sensitivity C-reactive protein are the average of the values obtained at the first two study visits. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.